Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Fast Is The Arthralgia Market Expected to Grow Between 2025 And 2029?
In recent years, the size of the arthralgia market has witnessed robust growth. The market will escalate from $5.2 billion in 2024 to $5.62 billion in 2025, recording a compound annual growth rate (CAGR) of 8.2%. The historical market expansion is linked to the growing occurrences of autoimmune diseases, the rise in associated risk factors, an uptick in obesity cases, an increase in arthralgia prevalence, and a surge in joint disorders prevalence.
We anticipate a robust expansion in the arthralgia market in the coming years. The market forecasts suggest a rise to$7.67 billion by 2029, with a compound annual growth rate (CAGR) of 8.1%. This predicted growth in the forthcoming period can be traced back to a heightened awareness about arthralgia, an increase in the elderly population, improved healthcare infrastructure, an escalated demand for less invasive treatments, and a growing occurrence of sports-related injuries. The forecast period will also witness major trends such as the incorporation of digital health solutions, innovative therapies, cell treatments, advancements in medical technologies, and considerable investments in research and development.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21104&type=smp
What Are the Primary Drivers Supporting the Market Growth of the Arthralgia Market?
The arthralgia market is poised for growth, driven by the rising instances of rheumatoid arthritis. This chronic autoimmune disorder primarily impacts joints, leading to inflammation, pain, and possible joint deterioration. Factors such as an aging demographic, genetic factors, changes in lifestyle, and environmental concerns linked to smoking and pollution contribute to the increase in cases of rheumatoid arthritis. This condition induces arthralgia through chronic joint inflammation, resulting in discomfort, stiffness, and ongoing damage. Arthritis Australia, a non-profit organization based in Australia, reported in February 2024 that arthritis cases in Australia could escalate from 4.11 million in 2025 to 5.39 million by 2040, with osteoarthritis rising from 2.35 million to 3.11 million and rheumatoid arthritis projected to reach 748,721. Hence, the surge in rheumatoid arthritis cases is propelling the arthralgia market’s expansion.
Which Primary Segments of the Arthralgia Market Are Driving Growth and Industry Transformations?
The arthralgiamarket covered in this report is segmented –
1) By Cause: Osteoarthritis; Rheumatoid Arthritis; Gout; Psoriatic Arthritis; Lupus; Injuries; Infections; Other Causes
2) By Treatment Type: Medications; Therapies; Surgical Interventions; Lifestyle And Home Remedies
3) By Route Of Administration: Oral; Injectable; Topical; Transdermal
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
5) By End User: Hospital; Clinics; Homecare Settings; Rehabilitation Centers
Subsegments:
1) By Osteoarthritis: Knee Osteoarthritis; Hip Osteoarthritis; Hand Osteoarthritis; Spine Osteoarthritis; Shoulder Osteoarthritis
2) By Rheumatoid Arthritis: Seropositive Rheumatoid Arthritis; Seronegative Rheumatoid Arthritis; Juvenile Rheumatoid Arthritis; Early-Onset Rheumatoid Arthritis
3) By Gout: Primary Gout; Secondary Gout; Gouty Arthritis
4) By Psoriatic Arthritis: Symmetric Psoriatic Arthritis; Asymmetric Psoriatic Arthritis; Psoriatic Spondylitis; Distal Interphalangeal Predominant Psoriatic Arthritis
5) By Lupus: Systemic Lupus Erythematosus (SLE); Discoid Lupus Erythematosus; Drug-induced Lupus; Neonatal Lupus
6) By Injuries: Sports-related Injuries; Trauma and Fractures; Sprains and Strains; Tendon or Ligament Damage
7) By Infections: Septic Arthritis; Viral Arthritis; Bacterial Infections; Fungal Infections
8) By Other Causes: Fibromyalgia; Overuse Injuries; Sarcoidosis; Ankylosing Spondylitis; Crystal-induced Arthritis
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=21104&type=smp
Which Regions Are Key Players in the Growth of the #What Are the Primary Drivers Supporting the Market Growth of the Arthralgia Market?# Market?
North America was the largest region in the arthralgia market in 2024. The regions covered in the arthralgia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Are the Most Significant Market Trends in the Arthralgia Market?
The dominant players in the arthralgia industry are prioritizing the creation of novel treatments, such as RMAT-assigned gene therapy, to offer patients advanced therapeutic options that result in lasting pain alleviation and enhanced joint mobility. RMAT-assigned gene therapy is a term used to reference treatments that have been awarded the Regenerative Medicine Advanced Therapy (RMAT) designation by the FDA. This designation accelerates the advancement and evaluation of groundbreaking gene therapies for severe or life-threatening illnesses. For example, in March 2024, the US pharmaceutical company Pacira BioSciences Inc. was accorded the Regenerative Medicine Advanced Therapy (RMAT) recognition for their product PCRX-201 (enekinragene inzadenovec) by the U.S. Food and Drug Administration (FDA). This is a cutting-edge, intra-articular gene therapy employing a helper-dependent adenovirus (HDAd) for addressing knee osteoarthritis. The therapy aims to generate interleukin-1 receptor antagonists (IL-1Ra). Pacira expressed satisfaction at being awarded the FDA’s inaugural RMAT label for a gene therapy targeting osteoarthritis, underlining the encouraging primary clinical findings hinting that PCRX-201 could potentially be a disease-altering treatment.
View the full report here:
https://www.thebusinessresearchcompany.com/report/arthralgia-global-market-report
What Parameters Are Used to Define the Arthralgia Market?
Arthralgia refers to pain in one or more joints, often without inflammation, and can result from various causes such as infections, autoimmune diseases, or injury. It is a symptom rather than a condition, typically indicating an underlying health issue affecting the joints.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21104
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model